Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETA

02 AUG

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name	
Canfield & Associates, Inc.	
2. Registrant Address ☐ Check if different than previously reported Address 801 Pennsylvania Avenue, NW City Washington State/Zip (or Country)	Suite 625 DC 20004
3. Principal Place of Business (if different from line 2)	
City Same State/Zip (or Country)	
·	mail (optional) 5. Senate ID # oril@canfieldassoc.com 7997-00125
7. Client Name  Self	6. House ID #
Pfizer, Inc.	3359-2009
INCOME OR EXPENSES - Complete Eith	
12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:	<b>EXPENSES</b> relating to lobbying activities for this reperiod were:
Less than \$10,000	Less than \$10,000
\$10,000 or more  >> \$ \$20,000.00 Income (nearest \$20,000)	_ \$10,000 or more
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
	☐ Method A. Reporting amounts using LDA definit
	☐ Method B. Reporting amounts under section 603 the Internal Revenue Code
	Method C. Reporting amounts under section 162 Internal Revenue Code
Signature	Date 8/14/2002
•	<del></del>

00020273368

Reg	istrant Name:	Canfield & Associates, Inc.	
Clie	nt Name:	Pfizer, Inc.	<u></u>
enga info	aged in lobbyin rmation as req	ng on behalf of the client during the reporti uested. Attach additional page(s) as needed	
	prescription S. 2244, Pres prescription S. 2536, Rx I rebate agree S. 2625, Med Medicare be S. 812, Grea generics earl	bying issues edicare Modernization and Prescription drugs to Medicare beneficiaries scription Drug Price Parity for Americal drugs from Cananda Flexibility for State Act, Issues related to ments to make outpatient prescription d licare Outpatient Prescription Drug Act neficiaries	Drug Act of 2002, Issues related to delivery of outpations Act, Issues related to permitting commercial important amending Social Security Act to permit states to enterlarge available to persons who do not qualify for Medic of 2002, Issues related to delivery of outpatient prescripts Act of 2001, Issues related to amending Hatch-Waxmer
17.	Department Executive O	Congress and Federal agencies contacted of Health & Human Services ffice of the President presentatives	☐ Check if None
18.	Name of each	n individual who acted as a lobbyist in this	issue area  Covered Official Position (if applicable)
	Blauwet, Ro	ger	
	Boston, Apr	1	
	Canfield, Ar	ne	
19.	Interest of ea	ch foreign entity in the specific issues listed	
Sign	ature		Date

00020273369

Reg	istrant Name:	Canfield & Associates, Inc.	
Clie	ent Name:	Pfizer, Inc.	
eng	aged in lobbyir	•	essary to reflect the general issue areas in which the registrant porting period. Using a separate page for each code, provide eeded.
15.	General issue	e area code TRD (one per p	page)
16.	Specific Lobb HR 3009, An		related to language on Doha agreement on TRIPS
17.		Congress and Federal agencies contact presentatives	ed
18.	Name of each	h individual who acted as a lobbyist in	this issue area  Covered Official Position (if applicable)
	Blauwet, Ro	aar	
	Boston, Apri		
	<del>-</del>		
	Canfield, An	nne	
19.	Interest of each	ch foreign entity in the specific issues	listed on line 16 above
Sigi	nature	tres)	Date 8/14/2002